Le Lézard
Classified in: Health
Subjects: RCL, CFG

Public advisory - Pediatrix Acetaminophen Oral Solution for children: One lot recalled due to potential risk of overdose


OTTAWA, ON, Jan. 17, 2024 /CNW/ -

Summary
Affected products

Product

DIN

Lot

Expiry

Pediatrix (Acetaminophen Oral Solution), 160mg/5mL

02027798

MC0079

Aug 2025

 

Issue

Teva Canada Ltd. is recalling one lot of Pediatrix Acetaminophen Oral Solution after routine product testing found a higher than acceptable amount of acetaminophen in the affected lot (approximately 185mg/5mL rather than the approved and labelled 160mg/5mL). This could lead to children receiving too much acetaminophen. Children may be especially at risk of the effects of acetaminophen overdose given their small size and developing bodies.

Signs of acetaminophen overdose include nausea, vomiting, lethargy, sweating, loss of appetite and pain in the upper part of the abdomen or stomach. Abdominal pain may be the first sign of liver damage and may not be apparent for 24 to 48 hours. Liver damage may result in liver failure or, in the most severe cases, death.

The product is available without a prescription and is used to relieve mild to moderate pain and fever in children from 2 to 11 years of age.

Health Canada is monitoring the company's recall and its implementation of any necessary corrective and preventative actions. It will inform the public if any new health risks are identified.

Given the limited scope of the recall, it will not have any impact on the general availability of children's acetaminophen products.

 What you should do

Également disponible en français

SOURCE Health Canada (HC)


These press releases may also interest you

at 07:30
The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, will host its VISIONS 2024 conference at the Chicago Marriott Downtown Magnificent Mile on June 21?22, 2024. This biennial...

at 07:30
Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new groundbreaking algorithm, SignalHF1, used...

at 07:30
The American Trucking Associations is calling attention to the negative consequences for highway safety and safety-sensitive industries that could result from the U.S. Drug Enforcement Administration's proposal to reschedule marijuana from a Schedule...

at 07:30
-    AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)-    Data to be presented from...

at 07:28
We are advised by OsteoStrong that journalists and other readers should disregard the news release, OsteoStrong Celebrates Success and Innovation at 11th Annual Global Franchise Owner Convention, issued May 9, 2024 over PR Newswire. SOURCE...

at 07:05
Precision BioSciences, Inc. , an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today...



News published on and distributed by: